Lumefantrine
| Clinical data | |
|---|---|
| Other names | benflumetol |
| AHFS/Drugs.com | International Drug Names |
| MedlinePlus | a609024 |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 99.7% |
| Metabolites | desbutyl-lumefantrine |
| Elimination half-life | 3-6 days |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.133.797 |
| Chemical and physical data | |
| Formula | C30H32Cl3NO |
| Molar mass | 528.94 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 130 to 132 °C (266 to 270 °F) |
| Solubility in water | 30.9ng/mL |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
Lumefantrine (or benflumetol) is an antimalarial drug. It is only used in combination with artemether. The term "co-artemether" is sometimes used to describe this combination.[1] Lumefantrine has a much longer half-life compared to artemether (3-6 days vs. 2 hours[2]), and is therefore thought to clear any residual parasites that remain after combination treatment.[3]
- ^ Toovey S, Jamieson A, Nettleton G (August 2003). "Successful co-artemether (artemether-lumefantrine) clearance of falciparum malaria in a patient with severe cholera in Mozambique". Travel Medicine and Infectious Disease. 1 (3): 177–179. doi:10.1016/j.tmaid.2003.09.002. PMID 17291911.
- ^ "Coartem - Highlights of prescribing information" (PDF). Novartis. August 2019. Retrieved 26 February 2025.
- ^ White NJ, van Vugt M, Ezzet F (August 1999). "Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine". Clinical Pharmacokinetics. 37 (2): 105–125. doi:10.2165/00003088-199937020-00002. PMID 10496300. S2CID 72714420.